INTERPRETIVE CRITERIA AND QUALITY-CONTROL PARAMETERS FOR TESTING BACTERIAL SUSCEPTIBILITY TO THE FLUOROQUINOLONE PD131628

被引:1
作者
BARRY, AL
FUCHS, PC
ALLEN, SD
TENOVER, FC
JORGENSEN, JH
RELLER, LB
机构
[1] ST VINCENT HOSP & MED CTR,PORTLAND,OR 97225
[2] INDIANA UNIV,MED CTR,INDIANAPOLIS,IN 46202
[3] CTR DIS CONTROL & PREVENT,ATLANTA,GA 30333
[4] UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284
[5] DUKE UNIV,MED CTR,DURHAM,NC 27710
关键词
D O I
10.1128/JCM.33.1.235-238.1995
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
For testing bacterial susceptibility to PD131628, a 5-mu g disk and the following tentative interpretive criteria may be used: greater than or equal to 19 mm for susceptible (MIC, less than or equal to 1.0 mu g/ml), 16 to 18 mm for intermediate (MIC, 2.0 mu g/ml), and less than or equal to 15 mm for resistant (MIC, greater than or equal to 4.0 mu g/ml). For standard quality control strains, the following limits are proposed: for Escherichia coli ATCC 25922, zones of 31 to 41 mm or a MIC of 0.002 to 0.016 mu g/ml; for Pseudomonas aeruginosa ATCC 27853, zones of 26 to 34 mm or a MIC of 0.12 to 0.5 mu g/ml; for Staphylococcus aureus ATCC 25923, zones of 27 to 33 mm; for Staphylococcus aureus ATCC 29213, a MIC of 0.03 to 0.12 mu g/ml; and for Enterococcus faecalis ATCC 29212, a MIC of 0.12 to 0.5 mu g/ml.
引用
收藏
页码:235 / 238
页数:4
相关论文
共 12 条
[1]  
[Anonymous], 1993, PERFORMANCE STANDARD
[2]  
BARRETT HS, 1991, DIAGN MICROBIOL INFE, V14, P389
[3]   METHODS FOR TESTING THE SUSCEPTIBILITY OF ANAEROBIC-BACTERIA TO 2 FLUOROQUINOLONE COMPOUNDS, PD-131628 AND CLINAFLOXACIN [J].
BARRY, AL ;
FUCHS, PC ;
CITRON, DM ;
ALLEN, SD ;
WEXLER, HM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (06) :893-900
[4]   ANTISTAPHYLOCOCCAL ACTIVITY OF THE FLUOROQUINOLONES CI-960, PD-131628, SPARFLOXACIN, OFLOXACIN AND CIPROFLOXACIN [J].
BARRY, AL ;
FUCHS, PC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (03) :168-171
[5]   INVITRO ANTIBACTERIAL ACTIVITIES OF PD-131628, A NEW 1,8-NAPHTHYRIDINE ANTIINFECTIVE AGENT [J].
COHEN, MA ;
HUBAND, MD ;
MAILLOUX, GB ;
YODER, SL ;
ROLAND, GE ;
DOMAGALA, JM ;
HEIFETZ, CL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (01) :141-146
[6]  
COOPER MA, 1992, J ANTIMICROB CHEMOTH, V25, P519
[7]   INVITRO SUSCEPTIBILITIES OF PSEUDOMONAS-AERUGINOSA AND PSEUDOMONAS SPP TO THE NEW FLUOROQUINOLONES CLINAFLOXACIN AND PD-131628 AND 9 OTHER ANTIMICROBIAL AGENTS [J].
FORD, AS ;
BALTCH, AL ;
SMITH, RP ;
RITZ, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (04) :523-532
[8]   MULTICENTER EVALUATION OF THE INVITRO ACTIVITIES OF 3 NEW QUINOLONES, SPARFLOXACIN, CI-960, AND PD-131,628, COMPARED WITH THE ACTIVITY OF CIPROFLOXACIN AGAINST 5,252 CLINICAL BACTERIAL ISOLATES [J].
FUCHS, PC ;
BARRY, AL ;
PFALLER, MA ;
ALLEN, SD ;
GERLACH, EH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :764-766
[9]   ANTIBACTERIAL ACTIVITY OF PD-131628 AND PROPOSED DISC DIFFUSION SUSCEPTIBILITY TEST CRITERIA [J].
FUCHS, PC ;
BARRY, AL ;
PFALLER, MA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 (06) :1147-1154
[10]   QUALITY-CONTROL LIMITS FOR AMPICILLIN, CARBENICILLIN, MEZLOCILLIN, AND PIPERACILLIN DISK DIFFUSION SUSCEPTIBILITY TESTS - A COLLABORATIVE STUDY [J].
GAVAN, TL ;
JONES, RN ;
BARRY, AL ;
FUCHS, PC ;
GERLACH, EH ;
MATSEN, JM ;
RELLER, LB ;
THORNSBERRY, C ;
THRUPP, LD .
JOURNAL OF CLINICAL MICROBIOLOGY, 1981, 14 (01) :67-72